American Journal of Hematology · 2007 · 26 citations · 14 references
MedicineHematologyPharmacologyDrug MetabolismHematologic OncologyMolecular OncologyDrug Metabolism GeneticsHematologic ToxicityHematopoietic ToxicityInborn Errors Of MetabolismAcute Myeloid Leukemia ProgressionChronic Low-dose ExposureCytogenetic AberrationsLeukemia CytogeneticsNeoplastic CytogeneticsThiopurine MetabolismThiopurine TherapyTpmt Genotype
Immunosuppressive thiopurines like azathioprine, 6-mercaptopurine, and thioguanine are commonly used in inflammatory and neoplastic disorders. A subset of these patients are genetically slow metabolizers due to point-mutations in enzyme thiopurine S-methyltransferase (TPMT), and are at a higher risk of hematologic toxicity and leukemogenesis. We present such a patient who was a slow metabolizer for azathioprine, and developed a rapidly lethal form acute myeloid leukemia after relatively low dose exposure to the drug. There was prominent hemophagocytic activity in the bone marrow, and cytogenetic analysis showed a complex karyotype with monosomy 7, but no involvement of chromosome 8.
14